These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19364250)

  • 41. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
    Dewey RB; Hutton JT; LeWitt PA; Factor SA
    Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
    Verhagen Metman L; Locatelli ER; Bravi D; Mouradian MM; Chase TN
    Neurology; 1997 Feb; 48(2):369-72. PubMed ID: 9040723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine].
    Merello M; Leiguarda R
    Medicina (B Aires); 1995; 55(1):5-10. PubMed ID: 7565037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of apomorphine on the bladder of parkinsonian patients].
    Aranda B; Cramer P; Adba MA
    J Urol (Paris); 1992; 98(1):25-9. PubMed ID: 1527394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
    Mauguière F; Broussolle E; Isnard J
    Electroencephalogr Clin Neurophysiol; 1993; 88(4):243-54. PubMed ID: 7688279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Apomorphine].
    Esteban Muñoz J
    Neurologia; 1995 Oct; 10(8):330-7. PubMed ID: 8554783
    [No Abstract]   [Full Text] [Related]  

  • 50. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
    Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Freezing of gait unresponsive to dopaminergic stimulation in patients with severe Parkinsonism].
    Vaamonde Gamo J; Cabello JP; Gallardo Alcañiz MJ; Flores Barragan JM; Carrasco García de León S; Ibañez Alonso RE
    Neurologia; 2010; 25(1):27-31. PubMed ID: 20388458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
    Grosset KA; Malek N; Morgan F; Grosset DG
    J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
    Deffond D; Durif F; Tournilhac M
    J Neurol Neurosurg Psychiatry; 1993 Jan; 56(1):101-3. PubMed ID: 8429309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Practical considerations in the use of apomorphine injectable.
    Bowron A
    Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of motor fluctuations in Parkinson's disease.
    Koller WC
    Eur Neurol; 1996; 36 Suppl 1():43-8. PubMed ID: 8791022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
    Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
    Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K; Hagell P; Odin P
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The motor response to repeated apomorphine administration in Parkinson's disease.
    Hughes AJ; Bishop S; Stern GM; Lees AJ
    Clin Neuropharmacol; 1991 Jun; 14(3):209-13. PubMed ID: 2070362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ; Sabatini U; Chollet F; Montastruc JL; Marc-Vergnes JP; Rascol A
    Adv Neurol; 1993; 60():419-21. PubMed ID: 8420165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.